These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 15500435)

  • 41. IIb/IIIa or not IIb/IIIa? That is the question.
    Redwood S
    Int J Clin Pract; 1999 Dec; 53(8):577. PubMed ID: 10692749
    [No Abstract]   [Full Text] [Related]  

  • 42. Platelet GPIIb/IIIa receptor antagonists in human ischemic brain disease.
    Seitz RJ; Siebler M
    Curr Vasc Pharmacol; 2008 Jan; 6(1):29-36. PubMed ID: 18220937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glycoprotein IIb/IIIa inhibition and long-term benefit: the stuff of dreams?
    Montalescot G
    Eur Heart J; 2004 Sep; 25(18):1562-4. PubMed ID: 15351154
    [No Abstract]   [Full Text] [Related]  

  • 44. Platelet glycoprotein IIb/IIIa antagonists: pharmacology and clinical developments.
    Kam PC; Egan MK
    Anesthesiology; 2002 May; 96(5):1237-49. PubMed ID: 11981166
    [No Abstract]   [Full Text] [Related]  

  • 45. Early clinical results with the new oral glycoprotein IIb/IIIa agents.
    Teirstein PS
    Am J Cardiol; 1999 May; 83(9A):12E-15E. PubMed ID: 10357576
    [No Abstract]   [Full Text] [Related]  

  • 46. Platelet glycoprotein IIb/IIIa inhibition with eptifibatide: prolongation of inhibition of aggregation in acute renal failure and reversal with hemodialysis.
    Sperling RT; Pinto DS; Ho KK; Carrozza JP
    Catheter Cardiovasc Interv; 2003 Aug; 59(4):459-62. PubMed ID: 12891606
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 1: design of potent and specific 3,9-diazaspiro[5.5]undecanes.
    Smyth MS; Rose J; Mehrotra MM; Heath J; Ruhter G; Schotten T; Seroogy J; Volkots D; Pandey A; Scarborough RM
    Bioorg Med Chem Lett; 2001 May; 11(10):1289-92. PubMed ID: 11392539
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Boersma E; Harrington RA; Moliterno DJ; White H; Simoons ML
    Lancet; 2002 Jul; 360(9329):342-3. PubMed ID: 12147403
    [No Abstract]   [Full Text] [Related]  

  • 49. Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 2: design of potent antagonists containing the 3-azaspiro[5.5]undecanes.
    Pandey A; Seroogy J; Volkots D; Smyth MS; Rose J; Mehrotra MM; Heath J; Ruhter G; Schotten T; Scarborough RM
    Bioorg Med Chem Lett; 2001 May; 11(10):1293-6. PubMed ID: 11392540
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [The history of the SET-UP study (or how difficult is neutrality in clinical research)].
    Tavazzi L; Maggioni AP
    Ital Heart J Suppl; 2000 Apr; 1(4):582-3. PubMed ID: 10832152
    [No Abstract]   [Full Text] [Related]  

  • 51. Relation between inhibition of platelet aggregation and clinical outcomes.
    Harrington RA; Kleiman NS; Granger CB; Ohman EM; Berkowitz SD
    Am Heart J; 1998 Oct; 136(4 Pt 2 Su):S43-50. PubMed ID: 9778087
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Eptifibatide: a cyclic peptide that selectively inhibits platelet glycoprotein IIb/IIIa.
    Heras M; Escolar G
    Drugs Today (Barc); 2000 May; 36(5):295-311. PubMed ID: 12861353
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 3: synthesis and SAR of potent and specific 2,8-diazaspiro[4.5]decanes.
    Mehrotra MM; Heath JA; Rose JW; Smyth MS; Seroogy J; Volkots DL; Ruhter G; Schotten T; Alaimo L; Park G; Pandey A; Scarborough RM
    Bioorg Med Chem Lett; 2002 Apr; 12(7):1103-7. PubMed ID: 11909727
    [TBL] [Abstract][Full Text] [Related]  

  • 54.
    Ha K; Zheng X; Kessinger CW; Mauskapf A; Li W; Kawamura Y; Orii M; Hilderbrand SA; Jaffer FA; McCarthy JR
    ACS Sens; 2021 Jun; 6(6):2225-2232. PubMed ID: 34056903
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glycoprotein IIb/IIIa inhibitors in the treatment of thromboembolic events related to endovascular treatment of cerebral aneurysms-systematic review and meta-analysis.
    Hasanpour M; Maleki S; Rezaee H; Aminzadeh B; Abbasi Shaye Z; Keykhosravi E
    Neuroradiol J; 2024 Apr; 37(2):152-163. PubMed ID: 36961079
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of salt form on chemical stability of an ester prodrug of a glycoprotein IIb/IIIa receptor antagonist in solid dosage forms.
    Badawy SI
    Int J Pharm; 2001 Jul; 223(1-2):81-7. PubMed ID: 11451634
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Crystallization of the OP-G2 Fab fragment: a fibrinogen mimic with specificity for the platelet glycoprotein IIb/IIIa.
    Celikel R; Williamson MM; Ni C; Ely KR
    Acta Crystallogr D Biol Crystallogr; 1993 Jul; 49(Pt 4):421-2. PubMed ID: 15299517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term administration of glycoprotein IIb/IIIa antagonists.
    Quinn M; Fitzgerald DJ
    Am Heart J; 1998 May; 135(5 Pt 2 Su):S113-8. PubMed ID: 9588390
    [No Abstract]   [Full Text] [Related]  

  • 59. Storing paraformaldehyde-fixed whole blood patient samples after chronic platelet glycoprotein IIb/IIIa blockade: core laboratory considerations.
    Murugesan SR; Gurbel PA; Serebruany VL
    Thromb Res; 1999 Aug; 95(4):201-3. PubMed ID: 10498390
    [No Abstract]   [Full Text] [Related]  

  • 60. Lesions and identification of crystalline precipitates of glycoprotein IIb-IIIa antagonists in the rat kidney.
    Levin S; Friedman RM; Cortez E; Hribar J; Nicholas M; Schlessinger S; Fouant M; Khan N
    Toxicol Pathol; 1999; 27(1):38-43. PubMed ID: 10367671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.